ClinicalTrials.gg
RecruitingNCT05853783Updated Nov 7, 2024

Evaluation of Oral Potentially Malignant Disorders (OPMDs) with STRATICYTE™

An observational study in Mouth Diseases, sponsored by Proteocyte Diagnostics Inc.. Recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-07.

Sponsored by Proteocyte Diagnostics Inc. · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
180
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 17 studies in Mouth Diseases with a site in United States — 2 open to participants now, 3 under way, none of them phase 3. Mouth Diseases · United States.

Started
2023
the only one that year
Observational
5 of 17
2 open now
Registered
16th of 17
by date
Lead sponsor
1 of 17
Proteocyte Diagnostics Inc.

Among the 17 studies in Mouth Diseases with a site in United States, this one is the only one that started in 2023, is one of 5 observational ones, and was the 16th registered.

Mouth Diseases

99 studies on the registry are indexed under Mouth Diseases; 19 are open to participants now.

Browse Mouth Diseases studies →

Open to participants now

2 of the 17 studies in Mouth Diseases with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Mouth Diseases studies recruiting now, 8 (67%) set no upper age limit and 2 (17%) stop at 75 or younger; none take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Mouth Diseases with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to validate the ability of the STRATICYTE™ predictive model to predict the transformation of oral potentially malignant disorders (OPMDs) to oral squamous cell carcinoma (OSCC) in a retrospective cohort of patients who received biopsies.

Read the detailed description

The study objectives are to:

  1. Evaluate STRATICYTE™ sensitivity and specificity in a cohort of patients that meet the inclusion/exclusion criteria.
  2. Identify patient and clinical characteristics influencing the sensitivity and specificity of the STRATICYTE™ model.
  3. Estimate the correlation between STRATICYTE™ outcome and time to a positive diagnosis of oral cancer.
03

Conditions studied

  • Mouth Diseases

Keywords

  • Leukoplakia
  • Erythroplakia
  • Erythroleukoplakia
  • Lesion
  • Oral epithelial dysplasia
  • S100A7 biomarker
  • S100A7 Immunohistochemistry Signature-based
  • Early Diagnosis
  • STRATICYTE
  • Oral neoplasia
  • Oral epithelial atypia
  • Hyperplasia
  • Hyperkeratosis
  • Potentially premalignant oral epithelial lesion
  • Oral potentially malignant disorders
  • Mild dysplasia
  • Moderate dysplasia
  • Severe dysplasia
  • Low-grade dyspalsia
  • High-grade dysplasia
  • Personalized medicine
  • Predictive Assay
  • Whole slide imaging
  • Computational pathology
  • Digital pathology
  • Oral potentially malignant lesion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The target population are patients presenting with an OPMD who have received a biopsy of their lesion. The study sample will be composed of patients with previously biopsied OPMDs from contracted clinics.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • From the archive, any patient who presents with clinically evident oral lesions and -proven dysplasia (punch or scalpel biopsies; any grade or classification system)
  • Patients with initial oral lesions with epithelial atypia suspicious for neoplasia, with:
  • No histological evidence of cancer with clinical follow-up data for a period of at least five years; or
  • OSCC development (histologic or documented evidence of invasive cancer).
  • Patients who had archived biopsy tissue blocks of a previous oral lesion(s) meeting the above criteria and retained at the same clinical center.

Exclusion criteria

Exclusion Criteria:

  • Patients with oral lesions or dysplasia with no indication of OSCC development or follow-up data of less than five years in non-OSCC patients.
  • Patients diagnosed with oral epithelial dysplasia concomitant with OSCC at the time of the 's original pathology report or a subsequent clinical note of cancer progression within three months post-biopsy.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
180 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • OPMDs that progressed to OSCC

    No dysplasia, mild, moderate, severe dysplasia, CIS

    Other: STRATICYTE™ Test

  • OPMDs that did not progress to OSCC

    No dysplasia, mild, moderate, severe dysplasia, CIS

    Other: STRATICYTE™ Test

Interventions

  • OtherSTRATICYTE™ Test

    Assessment for risk of progression to oral cancer

    Also known as: S100A7 Immunohistochemistry Signature-based Test

06

What researchers measure

Primary outcomes

  1. Sensitivity and Specificity

    Standard measures of accuracy calculated using cross-tabulation of predicted risk category and confirmed cancer progression over a 5-year period from biopsy

    Time frame: 5 years

  2. Survival analysis

    Kaplan-Meier analyses to compare time to a positive diagnosis of oral cancer between patients/biopsies with a STRATICYTE™ classification of Low- and Elevated-Risk.

    Time frame: 5 years

Secondary outcomes

  1. AUC

    Area under the receiver operator curve

    Time frame: 5 years

  2. C-index (Harrell's)

    From all possible pairs of patients, compute the number of concordant and discordant pairs. Compute C-index as the proportion of all possible pairs that are concordant.

    Time frame: 5 years

07

Study locations

1 of 5 sites recruiting
  • The University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
    Completed

    Not enrolling at this site.

  • Loma Linda University
    Loma Linda, California 92350, United States
    Completed

    Not enrolling at this site.

  • Minnesota Oral and Facial Surgery
    Minneapolis, Minnesota 55415, United States
    Withdrawn

    Not enrolling at this site.

  • MD Anderson Cancer Cetner
    Houston, Texas 44907, United States
    Recruiting
    • Andrew G Sikora, MD, PhD · Contact
  • UTHealth Houston School of Dentistry
    Houston, Texas 77054, United States
    Completed

    Not enrolling at this site.

08

References and documents

Publications

  • Hwang, J.T.K., Dammling, C., McCord, C. et al. External Validation of Straticyte™, a Quantitative Biomarker-Based Risk Assay in Predicting Oral Cancer. J. Maxillofac. Oral Surg. (2024). https://doi.org/10.1007/s12663-024-02362-7
  • Ralhan R, Desouza LV, Matta A, Tripathi SC, Ghanny S, Datta Gupta S, Bahadur S, Siu KW. Discovery and verification of head-and-neck cancer biomarkers by differential protein expression analysis using iTRAQ labeling, multidimensional liquid chromatography, and tandem mass spectrometry. Mol Cell Proteomics. 2008 Jun;7(6):1162-73. doi: 10.1074/mcp.M700500-MCP200. Epub 2008 Mar 13. PubMed 18339795 ↗
  • Ralhan R, Desouza LV, Matta A, Tripathi SC, Ghanny S, Dattagupta S, Thakar A, Chauhan SS, Siu KW. iTRAQ-multidimensional liquid chromatography and tandem mass spectrometry-based identification of potential biomarkers of oral epithelial dysplasia and novel networks between inflammation and premalignancy. J Proteome Res. 2009 Jan;8(1):300-9. doi: 10.1021/pr800501j. PubMed 19072117 ↗
  • Tripathi SC, Matta A, Kaur J, Grigull J, Chauhan SS, Thakar A, Shukla NK, Duggal R, DattaGupta S, Ralhan R, Siu KW. Nuclear S100A7 is associated with poor prognosis in head and neck cancer. PLoS One. 2010 Aug 3;5(8):e11939. doi: 10.1371/journal.pone.0011939. PubMed 20689826 ↗
  • Kaur J, Matta A, Kak I, Srivastava G, Assi J, Leong I, Witterick I, Colgan TJ, Macmillan C, Siu KW, Walfish PG, Ralhan R. S100A7 overexpression is a predictive marker for high risk of malignant transformation in oral dysplasia. Int J Cancer. 2014 Mar 15;134(6):1379-88. doi: 10.1002/ijc.28473. Epub 2013 Oct 8. PubMed 24122701 ↗
  • Hwang JT, Gu YR, Shen M, Ralhan R, Walfish PG, Pritzker KP, Mock D. Individualized five-year risk assessment for oral premalignant lesion progression to cancer. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Mar;123(3):374-381. doi: 10.1016/j.oooo.2016.11.004. Epub 2016 Nov 22. PubMed 28110942 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2023 (actual). Primary completion is estimated for Dec 2024, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2023
First posted
May 11, 2023
StartActual
Jan 1, 2023
Primary completionEst.
Dec 2024
CompletionEst.
Dec 2024
Last update
Nov 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05853783
Lead sponsor
Proteocyte Diagnostics Inc.
Responsible party
Sponsor
First posted
May 11, 2023
Start date
Jan 1, 2023
Primary completion
Dec 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Nov 7, 2024

Study contacts

Jody Filkowski, BSc, MSc, PhD
Contact
Jody.Filkowski@medlior.com
1-825-305-0749
Jason TK Hwang, HBSc, MSc, PhD
Contact
jhwang@proteocyte.com
1-647-255-1370
Simon W Young, DDS, MD, PhD
principal investigator · UTHealthHouston

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion